LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 64

Search options

  1. Article ; Online: Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress.

    Croushore, Emma E / Koppenhafer, Stacia L / Goss, Kelli L / Geary, Elizabeth L / Gordon, David J

    Cancer research communications

    2023  Volume 3, Issue 8, Page(s) 1580–1593

    Abstract: Ribonucleotide reductase (RNR) catalyzes the rate-limiting step in the synthesis of deoxyribonucleosides and is required for DNA replication. Multiple types of cancer, including Ewing sarcoma tumors, are sensitive to RNR inhibitors or a reduction in the ... ...

    Abstract Ribonucleotide reductase (RNR) catalyzes the rate-limiting step in the synthesis of deoxyribonucleosides and is required for DNA replication. Multiple types of cancer, including Ewing sarcoma tumors, are sensitive to RNR inhibitors or a reduction in the levels of either the RRM1 or RRM2 subunits of RNR. However, the polypharmacology and off-target effects of RNR inhibitors have complicated the identification of the mechanisms that regulate sensitivity and resistance to this class of drugs. Consequently, we used a conditional knockout (CRISPR/Cas9) and rescue approach to target RRM1 in Ewing sarcoma cells and identified that loss of the RRM1 protein results in the upregulation of the expression of multiple members of the activator protein-1 (AP-1) transcription factor complex, including c-Jun and c-Fos, and downregulation of c-Myc. Notably, overexpression of c-Jun and c-Fos in Ewing sarcoma cells is sufficient to inhibit cell growth and downregulate the expression of the c-Myc oncogene. We also identified that the upregulation of AP-1 is mediated, in part, by SLFN11, which is a replication stress response protein that is expressed at high levels in Ewing sarcoma. In addition, small-molecule inhibitors of RNR, including gemcitabine, and histone deacetylase inhibitors, which reduce the level of the RRM1 protein, also activate AP-1 signaling and downregulate the level of c-Myc in Ewing sarcoma. Overall, these results provide novel insight into the critical pathways activated by loss of RNR activity and the mechanisms of action of inhibitors of RNR.
    Significance: RNR is the rate-limiting enzyme in the synthesis of deoxyribonucleotides. Although RNR is the target of multiple chemotherapy drugs, polypharmacology and off-target effects have complicated the identification of the precise mechanism of action of these drugs. In this work, using a knockout-rescue approach, we identified that inhibition of RNR upregulates AP-1 signaling and downregulates the level of c-Myc in Ewing sarcoma tumors.
    MeSH term(s) Humans ; Sarcoma, Ewing/drug therapy ; Transcription Factor AP-1/genetics ; Neuroectodermal Tumors, Primitive, Peripheral ; Signal Transduction/genetics ; Proto-Oncogene Proteins c-fos/genetics ; Ribonucleotide Reductases ; Craniocerebral Trauma ; DNA Replication/genetics ; Nuclear Proteins
    Chemical Substances Transcription Factor AP-1 ; Proto-Oncogene Proteins c-fos ; Ribonucleotide Reductases (EC 1.17.4.-) ; SLFN11 protein, human ; Nuclear Proteins
    Language English
    Publishing date 2023-08-17
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ISSN 2767-9764
    ISSN (online) 2767-9764
    DOI 10.1158/2767-9764.CRC-23-0268
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Symmetry of bilateral hallux valgus deformity: A radiographic study.

    Crooks, Sophie A / Lewis, Thomas L / Ray, Robbie / Gordon, David J

    Clinical anatomy (New York, N.Y.)

    2021  Volume 35, Issue 4, Page(s) 414–420

    Abstract: Hallux valgus (HV) is a common anatomical deformity leading to pain and difficulty with footwear and mobility. Bilateral HV deformity is much more common than unilateral although it remains unclear whether the severity of deformity is equal between feet. ...

    Abstract Hallux valgus (HV) is a common anatomical deformity leading to pain and difficulty with footwear and mobility. Bilateral HV deformity is much more common than unilateral although it remains unclear whether the severity of deformity is equal between feet. The objective was to investigate the severity and symmetry of HV in patients with bilateral symptomatic deformity presenting for surgery. Weight-bearing radiographs of patients presenting with symptomatic bilateral HV were reviewed. The hallux valgus angle (HVA) and intermetatarsal angle (IMA) were measured and classified as mild, moderate, or severe. Left-to-right comparison was undertaken to assess whether the degree of deformity was similar for each foot. The relationship between age, HVA, and IMA was also assessed. Between July 2014 and June 2020, 322 ft (161 patients with bilateral deformity) underwent corrective HV surgery. Of those, 6.8%, 64.6%, and 28.4% were classified as mild, moderate, and severe, respectively on the left side, and on the right 6.2%, 67.7%, and 26.1% were classified as mild, moderate, and severe respectively. There was no statistically significant difference between feet for either IMA (p = 0.06) or HVA (p = 0.85). There was a moderate correlation (R = 0.41, p ≤ 0.001) between HVA and IMA. There was only a 'weak' or 'very weak' correlation between age and HVA or IMA. Patients presenting for surgery with symptomatic bilateral HV have symmetrical moderate radiographic deformity at the time they present for consideration of surgical intervention.
    MeSH term(s) Foot ; Hallux Valgus/diagnostic imaging ; Hallux Valgus/surgery ; Humans ; Metatarsal Bones/surgery ; Radiography ; Retrospective Studies ; Treatment Outcome ; Weight-Bearing
    Language English
    Publishing date 2021-09-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1025505-9
    ISSN 1098-2353 ; 0897-3806
    ISSN (online) 1098-2353
    ISSN 0897-3806
    DOI 10.1002/ca.23772
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Third-Generation Minimally Invasive Chevron and Akin Osteotomies (MICA) in Hallux Valgus Surgery: Two-Year Follow-up of 292 Cases.

    Lewis, Thomas L / Ray, Robbie / Miller, George / Gordon, David J

    The Journal of bone and joint surgery. American volume

    2021  Volume 103, Issue 13, Page(s) 1203–1211

    Abstract: Background: There is interest in hallux valgus deformity correction using internal fixation with the minimally invasive chevron and Akin osteotomies (MICA) technique. The objective of this study was to assess the correction measured on postoperative ... ...

    Abstract Background: There is interest in hallux valgus deformity correction using internal fixation with the minimally invasive chevron and Akin osteotomies (MICA) technique. The objective of this study was to assess the correction measured on postoperative radiographs and clinical outcomes, using validated outcome measures, at 2 years following third-generation MICA.
    Methods: This is a prospective single-surgeon case series of 333 consecutive feet that underwent MICA surgery between July 2014 and April 2018. The primary clinical outcome measures included the Manchester-Oxford Foot Questionnaire (MOXFQ), EuroQol-5 Dimensions-5 Level (EQ-5D-5L) Index, EuroQol-visual analogue scale (EQ-VAS), and a VAS for pain (VAS-pain). Secondary outcome measures included radiographic parameters and complication rates.
    Results: Preoperative and 2-year postoperative patient-reported outcome measures (PROMs) were collected for 292 feet (87.7%). At a minimum 2-year follow-up, the MOXFQ scores (mean ± standard deviation [SD]) had improved in each domain-i.e., reduced from 44.5 ± 21.0 preoperatively to 9.4 ± 15.8 postoperatively for pain (p < 0.001), from 38.7 ± 23.4 to 6.5 ± 14.6 for walking and standing (p < 0.001), and from 48.0 ± 22.3 to 6.6 ± 13.5 for social interaction (p < 0.001). The VAS-pain score improved from 31.4 ± 22.7 preoperatively to 8.4 ± 16.4 at the 2-year follow-up (p < 0.001), the 1-2 intermetatarsal angle was reduced from 15.3° ± 3.6° preoperatively to 5.7° ± 3.2° at the 2-year follow-up (p < 0.001), and the hallux valgus angle was reduced from 32.9° ± 10.2° to 8.7° ± 5.2° (p < 0.001).
    Conclusions: The third-generation MICA provided significant improvement in clinical outcome measures at the 2-year follow-up and can be successfully used for correction of a range of hallux valgus deformities with a low rate of symptomatic recurrence.
    Level of evidence: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Bone Screws/adverse effects ; Female ; Follow-Up Studies ; Hallux Valgus/diagnostic imaging ; Hallux Valgus/surgery ; Humans ; Male ; Middle Aged ; Minimally Invasive Surgical Procedures/statistics & numerical data ; Osteotomy/methods ; Osteotomy/statistics & numerical data ; Outcome Assessment, Health Care ; Pain Measurement/methods ; Postoperative Complications/etiology ; Prospective Studies ; Regression Analysis ; Selection Bias ; Standing Position ; Surveys and Questionnaires ; Time Factors ; Walking ; Young Adult
    Language English
    Publishing date 2021-03-19
    Publishing country United States
    Document type Journal Article ; Observational Study
    ZDB-ID 220625-0
    ISSN 1535-1386 ; 0021-9355
    ISSN (online) 1535-1386
    ISSN 0021-9355
    DOI 10.2106/JBJS.20.01178
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: The Politics of Accountability in Networked Urban Climate Governance

    Gordon, David J.

    Global environmental politics

    2016  Volume 16, Issue 2, Page(s) 82

    Language English
    Document type Article
    ZDB-ID 2182717-5
    ISSN 1526-3800
    Database Current Contents Nutrition, Environment, Agriculture

    More links

    Kategorien

  5. Article: An Uneasy Equilibrium: The Coordination of Climate Governance in Federated Systems

    Gordon, David J.

    Global environmental politics

    2015  Volume 15, Issue 2, Page(s) 121

    Language English
    Document type Article
    ZDB-ID 2182717-5
    ISSN 1526-3800
    Database Current Contents Nutrition, Environment, Agriculture

    More links

    Kategorien

  6. Article ; Online: Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.

    Goss, Kelli L / Gordon, David J

    Oncotarget

    2016  Volume 7, Issue 39, Page(s) 63003–63019

    Abstract: There is a critical need in cancer therapeutics to identify targeted therapies that will improve outcomes and decrease toxicities compared to conventional, cytotoxic chemotherapy. Ewing sarcoma is a highly aggressive bone and soft tissue cancer that is ... ...

    Abstract There is a critical need in cancer therapeutics to identify targeted therapies that will improve outcomes and decrease toxicities compared to conventional, cytotoxic chemotherapy. Ewing sarcoma is a highly aggressive bone and soft tissue cancer that is caused by the EWS-FLI1 fusion protein. Although EWS-FLI1 is specific for cancer cells, and required for tumorigenesis, directly targeting this transcription factor has proven challenging. Consequently, targeting unique dependencies or key downstream mediators of EWS-FLI1 represent important alternative strategies. We used gene expression data derived from a genetically defined model of Ewing sarcoma to interrogate the Connectivity Map and identify a class of drugs, iron chelators, that downregulate a significant number of EWS-FLI1 target genes. We then identified ribonucleotide reductase M2 (RRM2), the iron-dependent subunit of ribonucleotide reductase (RNR), as one mediator of iron chelator toxicity in Ewing sarcoma cells. Inhibition of RNR in Ewing sarcoma cells caused apoptosis in vitro and attenuated tumor growth in an in vivo, xenograft model. Additionally, we discovered that the sensitivity of Ewing sarcoma cells to inhibition or suppression of RNR is mediated, in part, by high levels of SLFN11, a protein that sensitizes cells to DNA damage. This work demonstrates a unique dependency of Ewing sarcoma cells on RNR and supports further investigation of RNR inhibitors, which are currently used in clinical practice, as a novel approach for treating Ewing sarcoma.
    Language English
    Publishing date 2016-09-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2560162-3
    ISSN 1949-2553 ; 1949-2553
    ISSN (online) 1949-2553
    ISSN 1949-2553
    DOI 10.18632/oncotarget.11416
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.

    Ostergaard, Jason / Jonart, Leslie M / Ebadi, Maryam / Koppenhafer, Stacia L / Gordon, David J / Gordon, Peter M

    British journal of haematology

    2021  Volume 194, Issue 6, Page(s) 1094–1098

    MeSH term(s) Animals ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Checkpoint Kinase 1/antagonists & inhibitors ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Drug Synergism ; Humans ; Mice ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Pyrazines/pharmacology ; Pyrazines/therapeutic use ; Pyrazoles/pharmacology ; Pyrazoles/therapeutic use
    Chemical Substances Protein Kinase Inhibitors ; Pyrazines ; Pyrazoles ; prexasertib ; Deoxycytidine (0W860991D6) ; gemcitabine (B76N6SBZ8R) ; Checkpoint Kinase 1 (EC 2.7.11.1)
    Language English
    Publishing date 2021-06-07
    Publishing country England
    Document type Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/bjh.17610
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Inhibitor of DNA binding 2 (ID2) regulates the expression of developmental genes and tumorigenesis in ewing sarcoma.

    Koppenhafer, Stacia L / Goss, Kelli L / Voigt, Ellen / Croushore, Emma / Terry, William W / Ostergaard, Jason / Gordon, Peter M / Gordon, David J

    Oncogene

    2022  Volume 41, Issue 20, Page(s) 2873–2884

    Abstract: Sarcomas are difficult to treat and the therapy, even when effective, is associated with long-term and life-threatening side effects. In addition, the treatment regimens for many sarcomas, including Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma, are ... ...

    Abstract Sarcomas are difficult to treat and the therapy, even when effective, is associated with long-term and life-threatening side effects. In addition, the treatment regimens for many sarcomas, including Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma, are relatively unchanged over the past two decades, indicating a critical lack of progress. Although differentiation-based therapies are used for the treatment of some cancers, the application of this approach to sarcomas has proven challenging. Here, using a CRISPR-mediated gene knockout approach, we show that Inhibitor of DNA Binding 2 (ID2) is a critical regulator of developmental-related genes and tumor growth in vitro and in vivo in Ewing sarcoma tumors. We also identified that homoharringtonine, which is an inhibitor of protein translation and FDA-approved for the treatment of leukemia, decreases the level of the ID2 protein and significantly reduces tumor growth and prolongs mouse survival in an Ewing sarcoma xenograft model. Furthermore, in addition to targeting ID2, homoharringtonine also reduces the protein levels of ID1 and ID3, which are additional members of the ID family of proteins with well-described roles in tumorigenesis, in multiple types of cancer. Overall, these results provide insight into developmental regulation in Ewing sarcoma tumors and identify a novel, therapeutic approach to target the ID family of proteins using an FDA-approved drug.
    MeSH term(s) Animals ; Carcinogenesis/genetics ; Cell Transformation, Neoplastic/genetics ; Genes, Developmental ; Homoharringtonine ; Humans ; Inhibitor of Differentiation Protein 2/genetics ; Mice ; Proteins/genetics ; Sarcoma, Ewing/drug therapy ; Sarcoma, Ewing/genetics ; Sarcoma, Ewing/metabolism
    Chemical Substances ID2 protein, human ; Inhibitor of Differentiation Protein 2 ; Proteins ; Homoharringtonine (6FG8041S5B)
    Language English
    Publishing date 2022-04-14
    Publishing country England
    Document type Journal Article
    ZDB-ID 639046-8
    ISSN 1476-5594 ; 0950-9232
    ISSN (online) 1476-5594
    ISSN 0950-9232
    DOI 10.1038/s41388-022-02310-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: City-networks, global climate governance, and the road to 1.5°C

    Gordon, David J / Craig A Johnson

    Current opinion in environmental sustainability. 2018 Feb., v. 30

    2018  

    Abstract: This article reviews existing scholarship on the ability of transnational city-networks to contribute to achieving a global 1.5°C target. Its principal observation is that city-networks have become increasingly involved in pooling resources, setting ... ...

    Abstract This article reviews existing scholarship on the ability of transnational city-networks to contribute to achieving a global 1.5°C target. Its principal observation is that city-networks have become increasingly involved in pooling resources, setting agendas, sharing policies, and reporting emissions reductions, but more needs to be known about how precisely transnational city-networks are achieving verifiable emissions reductions at the urban scale. The article identifies a focus in contemporary research on direct and indirect pathways through which city-networks can potentially effect transformative change, and highlights four key issues in need of further research: burden-sharing within and across city-networks; the suite of possible policy options they are embracing and endorsing; the role and voice of marginal cities and vulnerable urban populations, and; the governance challenges related to moving from experimentation to collective global effect.
    Keywords cities ; climate ; emissions ; governance ; issues and policy ; urban population
    Language English
    Dates of publication 2018-02
    Size p. 35-41.
    Publishing place Elsevier B.V.
    Document type Article
    ZDB-ID 2514810-2
    ISSN 1877-3435
    ISSN 1877-3435
    DOI 10.1016/j.cosust.2018.02.011
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  10. Article ; Online: Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.

    Koppenhafer, Stacia L / Goss, Kelli L / Terry, William W / Gordon, David J

    Molecular cancer research : MCR

    2019  Volume 18, Issue 1, Page(s) 91–104

    Abstract: Inhibition of ribonucleotide reductase (RNR), the rate-limiting enzyme in the synthesis of deoxyribonucleotides, causes DNA replication stress and activates the ataxia telangiectasia and rad3-related protein (ATR)-checkpoint kinase 1 (CHK1) pathway. ... ...

    Abstract Inhibition of ribonucleotide reductase (RNR), the rate-limiting enzyme in the synthesis of deoxyribonucleotides, causes DNA replication stress and activates the ataxia telangiectasia and rad3-related protein (ATR)-checkpoint kinase 1 (CHK1) pathway. Notably, a number of different cancers, including Ewing sarcoma tumors, are sensitive to the combination of RNR and ATR-CHK1 inhibitors. However, multiple, overlapping mechanisms are reported to underlie the toxicity of ATR-CHK1 inhibitors, both as single agents and in combination with RNR inhibitors, toward cancer cells. Here, we identified a feedback loop in Ewing sarcoma cells in which inhibition of the ATR-CHK1 pathway depletes RRM2, the small subunit of RNR, and exacerbates the DNA replication stress and DNA damage caused by RNR inhibitors. Mechanistically, we identified that the inhibition of ATR-CHK1 activates CDK2, which targets RRM2 for degradation via the proteasome. Similarly, activation of CDK2 by inhibition or knockdown of the WEE1 kinase also depletes RRM2 and causes DNA damage and apoptosis. Moreover, we show that the concurrent inhibition of ATR and WEE1 has a synergistic effect in Ewing sarcoma cells. Overall, our results provide novel insight into the response to DNA replication stress, as well as a rationale for targeting the ATR, CHK1, and WEE1 pathways, in Ewing sarcoma tumors. IMPLICATIONS: Targeting the ATR, CHK1, and WEE1 kinases in Ewing sarcoma cells activates CDK2 and increases DNA replication stress by promoting the proteasome-mediated degradation of RRM2.
    MeSH term(s) Apoptosis/physiology ; Ataxia Telangiectasia Mutated Proteins/antagonists & inhibitors ; Ataxia Telangiectasia Mutated Proteins/metabolism ; Cell Cycle Proteins/antagonists & inhibitors ; Cell Line, Tumor ; Cell Proliferation ; Checkpoint Kinase 1/antagonists & inhibitors ; Checkpoint Kinase 1/metabolism ; Cyclin-Dependent Kinase 2/metabolism ; DNA Damage ; DNA Repair ; Enzyme Inhibitors/pharmacology ; HEK293 Cells ; Humans ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Pyrazoles/pharmacology ; Pyrimidinones/pharmacology ; Ribonucleoside Diphosphate Reductase/metabolism ; Sarcoma, Ewing/drug therapy ; Sarcoma, Ewing/genetics ; Sarcoma, Ewing/metabolism ; Sarcoma, Ewing/pathology ; Transfection
    Chemical Substances Cell Cycle Proteins ; Enzyme Inhibitors ; Pyrazoles ; Pyrimidinones ; ribonucleotide reductase M2 (EC 1.17.4.-) ; Ribonucleoside Diphosphate Reductase (EC 1.17.4.1) ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; WEE1 protein, human (EC 2.7.10.2) ; ATR protein, human (EC 2.7.11.1) ; Ataxia Telangiectasia Mutated Proteins (EC 2.7.11.1) ; CHEK1 protein, human (EC 2.7.11.1) ; Checkpoint Kinase 1 (EC 2.7.11.1) ; CDK2 protein, human (EC 2.7.11.22) ; Cyclin-Dependent Kinase 2 (EC 2.7.11.22) ; adavosertib (K2T6HJX3I3)
    Language English
    Publishing date 2019-10-24
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2098788-2
    ISSN 1557-3125 ; 1541-7786
    ISSN (online) 1557-3125
    ISSN 1541-7786
    DOI 10.1158/1541-7786.MCR-19-0585
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top